Assembly of targeting complexes driven by a single-chain antibody

被引:5
作者
Backer, MV [1 ]
Elliot, J [1 ]
Gaynutdinov, TI [1 ]
Backer, JM [1 ]
机构
[1] SibTech Inc, Newington, CT 06111 USA
关键词
targeted drug delivery; scFv antibody;
D O I
10.1016/j.jim.2004.03.011
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Rapid development in design and production of recombinant antibodies and antibody fragments specific for cell surface markers opens new opportunities for targeted delivery of therapeutic or imaging agents. However, the progress in this field is slowed by inactivation of many antibodies by chemical conjugation of payloads and by lack of internalization of complexes formed on the cell surface. Here, we describe conversion of a non-internalizing single chain Fv (scFv) antibody P4G7 specific for vascular endothelial growth factor receptor 2 (VEGFR-2) into a targeting protein (Hu-P4G7) for assembly of a novel type of targeting complexes. Hu-P4G7 contains an N-terminal "docking" Hu-tag, a 15-aa fragment of human RNase 1, capable of high affinity binding of S-protein fragment of human RNase I or bovine RNase A. Purified Hu-P4G7 and complexes of Hu-P4G7 with S-protein bind both soluble and full-length cellular VEGFR-2. To assemble targeted DNA delivery complexes, S-protein modified with a DNA condensing agent was "docked" to Hu-P4G7, and then loaded with luciferase plasmid DNA. As expected for a non-internalizing targeting protein, Hu-P4G7-based complexes did not deliver DNA in VEGFR-2 expressing cells. However, in the presence of vascular endothelial growth factor (VEGF), these complexes selectively delivered DNA into the cells overexpressing VEGFR-2 suggesting that even a non-internalizing scFv antibody can be used for targeted intracellular drug delivery. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:37 / 45
页数:9
相关论文
共 14 条
  • [1] Humanized docking system for assembly of targeting drug delivery complexes
    Backer, MV
    Gaynutdinov, TI
    Gorshkova, II
    Crouch, RJ
    Hu, T
    Aloise, R
    Arab, M
    Przekop, K
    Backer, JA
    [J]. JOURNAL OF CONTROLLED RELEASE, 2003, 89 (03) : 499 - 511
  • [2] Molecular vehicles for targeted drug delivery
    Backer, MV
    Aloise, R
    Przekop, K
    Stoletov, K
    Backer, JM
    [J]. BIOCONJUGATE CHEMISTRY, 2002, 13 (03) : 462 - 467
  • [3] Functionally active VEGF fusion proteins
    Backer, MV
    Backer, JM
    [J]. PROTEIN EXPRESSION AND PURIFICATION, 2001, 23 (01) : 1 - 7
  • [4] Targeting endothelial cells overexpressing VEGFR-2: Selective toxicity of Shiga-like toxin-VEGF fusion proteins
    Backer, MV
    Backer, JM
    [J]. BIOCONJUGATE CHEMISTRY, 2001, 12 (06) : 1066 - 1073
  • [5] BACKER MV, 2004, UNPUB BIOCONJUG CHEM
  • [6] BROWN LF, 1993, AM J PATHOL, V143, P1255
  • [7] EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) AND ITS RECEPTORS IN BREAST-CANCER
    BROWN, LF
    BERSE, B
    JACKMAN, RW
    TOGNAZZI, K
    GUIDI, AJ
    DVORAK, HF
    SENGER, DR
    CONNOLLY, JL
    SCHNITT, SJ
    [J]. HUMAN PATHOLOGY, 1995, 26 (01) : 86 - 91
  • [8] Dübel S, 1999, TUMOR TARGET, V4, P37
  • [9] Chimeric ribonuclease as a source of human adapter protein for targeted drug delivery
    Gaynutdinov, TI
    Myshkin, E
    Backer, JM
    Backer, MV
    [J]. PROTEIN ENGINEERING, 2003, 16 (10): : 771 - 775
  • [10] Characterization of a soluble vascular endothelial growth factor receptor immunoglobulin chimera
    Kaplan, JB
    Sridharan, L
    Zaccardi, JA
    DougherVermazen, M
    Terman, BI
    [J]. GROWTH FACTORS, 1997, 14 (04) : 243 - 256